Company
Sensorion SA
Headquarters: Montpellier, France
Employees: 34
CEO: Ms. Nawal Ouzren
Market Cap
€207.1 Million
EUR as of Jan. 1, 2025
US$215.5 Million
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Sensorion SA, a clinical-stage biopharmaceutical company, develops therapies for the treatment of inner ear disorders in France. It engages in developing USHER-GT, a gene therapy development program to restore inner ear function for patients suffering from usher syndrome Type 1; OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. The company's pipeline includes various products in development stage for restoring, treating, and preventing inner ear related disorders. Sensorion SA has a collaboration agreement with Institut Pasteur for gene therapy program to restore auditory functions; and a strategic collaboration with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. The company was founded in 2009 and is headquartered in Montpellier, France.
Stocks & Indices
Sensorion SA has the following listings and related stock indices.
Stock: Euronext: ALSEN wb_incandescent
Stock: FSX: RFM wb_incandescent
Stock: XSTU: RFM wb_incandescent